Mr. Hughes’ recent representations include:
- MBX Biosciences in its $35 million Series A financing
- Monte Rosa Therapeutics in its $32.5 million Series A financing
- Axcella Health in its $60.1 million follow-on offering and subsequent $35 million “at the market” offering
- Intellia Therapeutics in connection with its $115 million follow-on offering and its expanded licensing agreement with Regeneron Pharmaceuticals
- Navitor Pharmaceuticals in its development and option agreement with Supernus Pharmaceuticals
- Avadel Pharmaceuticals in its $65 million PIPE financing transaction
Mr. Hughes is a member of the CFA Society Boston and the Boston Bar Association.